All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

EFFICACY, SAFETY AND IMMUNOGENICITY FROM WEEK 30 TO WEEK 54 IN A RANDOMISED, DOUBLE-BLIND PHASE III STUDY COMPARING A PROPOSED INFLIXIMAB BIOSIMILAR (PF-06438179/GP1111) WITH REFERENCE INFLIXIMAB

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62157124%3A16370%2F18%3A43876872" target="_blank" >RIV/62157124:16370/18:43876872 - isvavai.cz</a>

  • Result on the web

    <a href="http://dx.doi.org/10.1136/annrheumdis-2018-eular.5121" target="_blank" >http://dx.doi.org/10.1136/annrheumdis-2018-eular.5121</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1136/annrheumdis-2018-eular.5121" target="_blank" >10.1136/annrheumdis-2018-eular.5121</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    EFFICACY, SAFETY AND IMMUNOGENICITY FROM WEEK 30 TO WEEK 54 IN A RANDOMISED, DOUBLE-BLIND PHASE III STUDY COMPARING A PROPOSED INFLIXIMAB BIOSIMILAR (PF-06438179/GP1111) WITH REFERENCE INFLIXIMAB

  • Original language description

    PF-06438179/GP1111 (GP1111) is an infliximab (IFX) biosimilar in development for the treatment of immune-mediated inflammatory diseases, including rheumatoid arthritis (RA). The efficacy, safety and immunogenicity of GP1111 and European reference IFX (IFX-EU) have been reported to be similar over 30 weeks (Wks). Results from TP2 (Wks 30?54) continued to show the absence of clinically meaningful differences in efficacy, safety and immunogenicity between patients with RA remaining on GP1111 or IFX-EU, or when blindly switched from IFX-EU to GP1111

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30104 - Pharmacology and pharmacy

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2018

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Annals of the rheumatic diseases

  • ISSN

    0003-4967

  • e-ISSN

  • Volume of the periodical

    77

  • Issue of the periodical within the volume

    červen

  • Country of publishing house

    GB - UNITED KINGDOM

  • Number of pages

    2

  • Pages from-to

    612-613

  • UT code for WoS article

    000444351001599

  • EID of the result in the Scopus database